

**CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER<sup>1,2</sup>**

**Part 1**

**Issued following an inspection in accordance with Art. 111(5) of Directive 2001/83/EC or Art. 15 of Directive 2001/20/EC\***

The Medicines Authority of Malta confirms the following:

**The manufacturer Finoso Pharma Private Ltd.**

**Site address 450, MN Park, Turkapally, Hyderabad 500 078, India.**

has been inspected in connection with marketing authorisation(s) listing manufacturers located outside of the European Economic Area in accordance with Art. 111(4) of Directive 2001/83/EC transposed in the following national legislation: **Article 101A (10) of the Medicines Act (Chapter 458 of the Laws of Malta).**

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **11<sup>th</sup> – 12<sup>th</sup> January 2020**, it is considered that it complies with the principles and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC<sup>3</sup> /Directive 91/412/EEC<sup>3</sup>


- 1 The certificate referred to in paragraph 111(5) of Directive 2001/83/EC, is also applicable to importers.
- 2 Guidance on the interpretation of this template can be found in the Help menu of Eudra GMDP database.
- 3 These requirements fulfil the GMP recommendations of WHO.


This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field.

This certificate is valid only when presented with all pages and both Parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

14<sup>th</sup> February 2020

  
.....  
**Dr. Mark Cilia<sup>1</sup>**  
**Director Inspectorate & Enforcement Directorate**  
**Medicines Authority**  
**Tel: 00356 234 39 119**  
**Fax: 00356 234 39 161**



**Part 2**

Human Medicinal Products
<b>1 MANUFACTURING OPERATIONS – MEDICINAL PRODUCTS</b>

<b>1.6</b>	<b>Quality Control testing</b> <i>1.6.3 Chemical/Physical</i>
------------	--

Any restrictions or clarifying remarks related to the scope of this certificate:  
**Testing is not intended for the purpose of batch certification and/or batch release by an EU QP.**

14<sup>th</sup> February 2020



.....  
**Dr. Mark Cilia<sup>1</sup>**  
**Director Inspectorate & Enforcement Directorate**  
**Medicines Authority**  
**Tel: 00356 234 39 119**  
**Fax: 00356 234 39 161**

<sup>1</sup> The signature, date and contact details should appear on each page of the certificate